Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 2/20 | 0.45 |
| ▸ | EGFR | P00533 | 8/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | ERBB3 | P21860 | 4/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | BCR | P11274 | 1/20 | 0.43 |
| ▸ | TNNI3K | Q59H18 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2063772 | 0.87 | MEN1 (0.48) | CFDMEN1KMT2ANPC1RAB9A | |
| SCHEMBL27345372 | 0.86 | EGFR (0.46) | CFDMEN1KMT2ANPC1RAB9A | |
| SCHEMBL27322736 | 0.86 | CFD (0.47) | CFDMEN1KMT2ANPC1RAB9A | |
| SCHEMBL27977809 | 0.85 | ENPP2 (0.55) | CFDMEN1KMT2AMAPTENPP2 | |
| SCHEMBL27338330 | 0.81 | MEN1 (0.50) | CFDMEN1KMT2ANPC1RAB9A | |
| SCHEMBL27318793 | 0.81 | EGFR (0.67) | CFDMEN1KMT2ANPC1RAB9A | |
| SCHEMBL27318729 | 0.80 | CFD (0.49) | CFDMEN1KMT2ANPC1RAB9A | |
| SCHEMBL27332161 | 0.80 | JAK3 (0.58) | MEN1KMT2ANPC1RAB9ATP53 | |
| SCHEMBL27323503 | 0.80 | EGFR (0.45) | CFDMEN1KMT2ANPC1RAB9A | |
| SCHEMBL27319709 | 0.79 | EGFR (0.58) | CFDMEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148388-B2 | 2,4 (4,6) pyrimidine derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2012-04-03 | — | — | US | disclosed |
| US-20100160310-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-06-24 | — | — | US | disclosed |
| CN-1047778-C | Pyrimido [5-4-d] pyrimidines, drugs containing these compounds, their use and process for preparing them | THOMAE GMBH DR K (DE) | 1999-12-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160310-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | NR1H3, NR1H2, NR0B1 | CFD 4518/4885MEN1 2788/4885KMT2A 2513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.